The COVID-19 pandemic presents substantial challenges for governments and providers
keen to provide effective treatments. The tensions between supply, uncertainty of which …

Oral antivirals are a potential 'game changer'for healthcare provision during the ongoing
coronavirus disease 2019 (COVID-19) pandemic. Whilst various parenteral treatments have …

Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …

Objectives A reappraisal of the validity of the conclusions of systematic reviews (SRs)
related to nirmatrelvir/ritonavir for the treatment of COVID-19. Methods An overview of SRs …

Abstract INDICATIONS NIR/RIT can be prescribed to treat mild-to-moderate COVID-19 in
patients age 12 years and older weighing at least 40 kg with positive results of direct SARS …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Oral nirmatrelvir plus ritonavir (Paxlovid™) is an effective treatment option for coronavirus
disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome …

For the treatment of mild to moderate COVID-19 in adults who are at high risk of progression
to severe COVID-19, including hospitalization or death. Paxlovid is the fourth drug—and first …

Highlights What are the main findings? Nirmatrelvir/Ritonavir, an oral treatment for COVID-
19, effectively reduces the risk of progressing to a more severe disease state for both the …